Reiterer et al. compared levels of circulating adiponectin between groups of critically ill patients and found that circulating adiponectin in patients with COVID-19 ARDS was decreased by 50–60% compared to non-COVID-19 controls with and without ARDS [20]. Here, ADIPOQ is linked to COVID-19.